- Home
- NQP vs DSGN Comparison
NQP vs DSGN Comparison
Compare NQP & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NQP
- DSGN
- Stock Information
- Founded
- NQP 1990
- DSGN 2017
- Country
- NQP United States
- DSGN United States
- Employees
- NQP N/A
- DSGN 54
- Industry
- NQP Trusts Except Educational Religious and Charitable
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- NQP Finance
- DSGN Health Care
- Exchange
- NQP Nasdaq
- DSGN Nasdaq
- Market Cap
- NQP 438.1M
- DSGN 353.9M
- IPO Year
- NQP N/A
- DSGN 2021
- Fundamental
- Price
- NQP $11.57
- DSGN $6.25
- Analyst Decision
- NQP
- DSGN Hold
- Analyst Count
- NQP 0
- DSGN 3
- Target Price
- NQP N/A
- DSGN $7.00
- AVG Volume (30 Days)
- NQP 58.4K
- DSGN 156.0K
- Earning Date
- NQP 01-01-0001
- DSGN 11-07-2024
- Dividend Yield
- NQP 3.21%
- DSGN N/A
- EPS Growth
- NQP N/A
- DSGN N/A
- EPS
- NQP N/A
- DSGN N/A
- Revenue
- NQP N/A
- DSGN N/A
- Revenue This Year
- NQP N/A
- DSGN N/A
- Revenue Next Year
- NQP N/A
- DSGN N/A
- P/E Ratio
- NQP N/A
- DSGN N/A
- Revenue Growth
- NQP N/A
- DSGN N/A
- 52 Week Low
- NQP $9.65
- DSGN $2.25
- 52 Week High
- NQP $11.89
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- NQP 29.23
- DSGN 52.20
- Support Level
- NQP $12.00
- DSGN $5.16
- Resistance Level
- NQP $12.11
- DSGN $6.43
- Average True Range (ATR)
- NQP 0.09
- DSGN 0.51
- MACD
- NQP -0.04
- DSGN -0.03
- Stochastic Oscillator
- NQP 4.31
- DSGN 57.67
About NQP Nuveen Pennsylvania Quality Municipal Income Fund
Nuveen Pennsylvania Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal and Pennsylvania income taxes and to enhance portfolio value relative to the municipal bond market by investing in municipal securities that are exempt from federal, Pennsylvania state and local income taxes. It invests a majority of its assets in securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.